Literature DB >> 28699479

MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment.

Ramona Moles1.   

Abstract

MicroRNAs are short non-coding RNAs involved in critical biological processes. In the past decade, the deregulation of miRNAs has been well-documented in a wide range of human diseases, including cancer. Overexpression and downregulation of miRNAs affect cellular pathways that contribute to carcinogenesis and tumor progression. This evidence makes miRNAs a suitable candidate for therapeutic applications and leads to developing strategies to manipulate their expression. Consistently, in vitro and in vivo studies show that Let-7, miR-10b, miR-21, miR-34, miR-155 and miR-221 are promising targets to develop miRNAs-based therapy for human malignancies. The purpose of this review is to discuss the different approaches that can be used to restore or reduce miRNAs expression in human cancer and the therapeutic implications. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  AntimiRNAs; Let-7; MiR-10b; MiR-155; MiR-21; MiR-221; MiR-34; cancer therapy; miRNAzzm321990therapeutic; miRNA mimics; tumor

Mesh:

Substances:

Year:  2017        PMID: 28699479     DOI: 10.2174/2211536606666170710183039

Source DB:  PubMed          Journal:  Microrna


  11 in total

1.  MiR-28-5p promotes human glioblastoma cell growth through inactivation of FOXO1.

Authors:  Guohua Zhu; Zengliang Wang; Maimaitili Mijiti; Guojia Du; Yandong Li; Geng Dangmurenjiafu
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

2.  A Feedback Loop between MicroRNA 155 (miR-155), Programmed Cell Death 4, and Activation Protein 1 Modulates the Expression of miR-155 and Tumorigenesis in Tongue Cancer.

Authors:  Shabir Zargar; Vivek Tomar; Vidyarani Shyamsundar; Ramshankar Vijayalakshmi; Kumaravel Somasundaram; Devarajan Karunagaran
Journal:  Mol Cell Biol       Date:  2019-03-01       Impact factor: 4.272

Review 3.  Messenger RNA Life-Cycle in Cancer Cells: Emerging Role of Conventional and Non-Conventional RNA-Binding Proteins?

Authors:  Lucie Coppin; Julie Leclerc; Audrey Vincent; Nicole Porchet; Pascal Pigny
Journal:  Int J Mol Sci       Date:  2018-02-25       Impact factor: 5.923

4.  miR-622 suppresses tumor formation by directly targeting VEGFA in papillary thyroid carcinoma.

Authors:  Qingjie Ma; Qiang Wen; Renjie Wang; Linlin Ji; Yue Yao; Mengshi Ma
Journal:  Onco Targets Ther       Date:  2018-03-16       Impact factor: 4.147

5.  A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis.

Authors:  Yixin Chen; Yanying Zhou; Fangwei Han; Yingyuan Zhao; Meijuan Tu; Yongtao Wang; Can Huang; Shicheng Fan; Panpan Chen; Xinpeng Yao; Lihuan Guan; Ai-Ming Yu; Frank J Gonzalez; Min Huang; Huichang Bi
Journal:  Theranostics       Date:  2020-06-01       Impact factor: 11.556

6.  Role of miR-520b in non-small cell lung cancer.

Authors:  Linlin Zhang; Shuangquan Yu
Journal:  Exp Ther Med       Date:  2018-09-12       Impact factor: 2.447

Review 7.  MicroRNA Post-transcriptional Regulation of the NLRP3 Inflammasome in Immunopathologies.

Authors:  Gulcin Tezcan; Ekaterina V Martynova; Zarema E Gilazieva; Alan McIntyre; Albert A Rizvanov; Svetlana F Khaiboullina
Journal:  Front Pharmacol       Date:  2019-05-01       Impact factor: 5.810

8.  SSRP1 promotes colorectal cancer progression and is negatively regulated by miR-28-5p.

Authors:  Wei Wu; Ke He; Qian Guo; Jingdi Chen; Mengjiao Zhang; Kai Huang; Dongmei Yang; Lu Wu; Yunchao Deng; Xu Luo; Honggang Yu; Qianshan Ding; Guoan Xiang
Journal:  J Cell Mol Med       Date:  2019-02-14       Impact factor: 5.310

9.  Bio responsive self-assembly of Au-miRNAs for targeted cancer theranostics.

Authors:  Weijuan Cai; Huan Feng; Liang Yin; Maonan Wang; Xuerui Jiang; Zhaojian Qin; Weiwei Liu; Chunmei Li; Hui Jiang; Yossi Weizmann; Xuemei Wang
Journal:  EBioMedicine       Date:  2020-04-07       Impact factor: 8.143

10.  Expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer.

Authors:  Xi-Han Jin; Sen Lu; Ai-Fen Wang
Journal:  BMC Cancer       Date:  2020-03-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.